文献速递精神分裂症与精神病性障碍会诊联络精神医学

改善精神分裂症患者躯体健康结局的药物与非药物干预:随机对照试验荟萃分析的再评价

The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.
PubMed 文献 · World Psychiatry · 2019-01-01

该再评价汇总了截至2018年6月1日的27项荟萃分析,涵盖128项荟萃分析的试验和47,231名精神分裂症谱系障碍参与者,比较了药物与非药物干预对体重、腰围、血压、血糖、血脂及运动能力等躯体健康结局的效果。最有效的减重干预为个体生活方式咨询(SMD=-0.98)和运动干预(SMD=-0.96),而现有证据仍有限,亟需更大规模试验。

要点

  • 个体生活方式咨询和运动干预减重效果最显著,SMD分别为-0.98和-0.96。
  • 阿立哌唑增效减腰围效果最佳(SMD=-1.10),托吡酯次之(SMD=-0.69)。
  • 仅运动干预能提高运动能力(SMD=1.81),饮食干预唯一显著改善舒张压。

核心结论

  • 现有药物与非药物干预对精神分裂症患者躯体健康结局的证据仍有限,亟需更大规模试验。

研究设计与样本

  • 检索截至2018年6月1日的主要数据库,纳入27项荟萃分析,代表128项荟萃分析的试验和47,231名研究参与者。
  • 纳入的荟萃分析质量普遍为充分或高,但其荟萃分析的研究质量较低。

主要发现

  • 减重最有效的干预为个体生活方式咨询(SMD=-0.98)和运动干预(SMD=-0.96),其次为心理教育(SMD=-0.77)、阿立哌唑增效(SMD=-0.73)、托吡酯(SMD=-0.72)、d-芬氟拉明(SMD=-0.54)和二甲双胍(SMD=-0.53)。
  • 减少腰围方面,阿立哌唑增效(SMD=-1.10)和托吡酯(SMD=-0.69)证据最佳,其次为饮食干预(SMD=-0.39)。
  • 饮食干预是唯一显著改善(舒张)血压的干预(SMD=-0.39)。
  • 降低血糖方面,从奥氮平换用喹硫平或阿立哌唑(SMD=-0.71)和二甲双胍(SMD=-0.65)效果最佳,其次为GLP-1受体激动剂(SMD=-0.39)、饮食干预(SMD=-0.37)和阿立哌唑增效(SMD=-0.34);胰岛素抵抗改善最显著为二甲双胍(SMD=-0.75)和罗格列酮(SMD=-0.44)。
  • 托吡酯对甘油三酯(SMD=-0.68)和LDL胆固醇(SMD=-0.80)效果最大,二甲双胍对总胆固醇(SMD=-0.51)和HDL胆固醇(SMD=0.45)有益效果最大;生活方式干预对甘油三酯、总胆固醇和LDL胆固醇效果较小(SMD=-0.35至-0.37);仅运动干预提高运动能力(SMD=1.81)。

临床怎么用

  • 针对精神分裂症患者躯体健康管理,可优先考虑个体生活方式咨询和运动干预以减重。
  • 对于代谢指标异常,可根据具体指标选择阿立哌唑增效、托吡酯、二甲双胍或换药等策略。

局限性

  • 荟萃分析纳入的原始研究质量较低,整体证据仍有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We summarized and compared meta-analyses of pharmacological and non-pharmacological interventions targeting physical health outcomes among people with schizophrenia spectrum disorders. Major databases were searched until June 1, 2018. Of 3,709 search engine hits, 27 meta-analyses were included, representing 128 meta-analyzed trials and 47,231 study participants. While meta-analyses were generally of adequate or high quality, meta-analyzed studies were less so. The most effective weight reduction interventions were individual lifestyle counseling (standardized mean difference, SMD=-0.98) and exercise interventions (SMD=-0.96), followed by psychoeducation (SMD=-0.77), aripiprazole augmentation (SMD=-0.73), topiramate (SMD=-0.72), d-fenfluramine (SMD=-0.54) and metformin (SMD=-0.53). Regarding waist circumference reduction, aripiprazole augmentation (SMD=-1.10) and topiramate (SMD=-0.69) demonstrated the best evidence, followed by dietary interventions (SMD=-0.39). Dietary interventions were the only to significantly improve (diastolic) blood pressure (SMD=-0.39). Switching from olanzapine to quetiapine or aripiprazole (SMD=-0.71) and metformin (SMD=-0.65) demonstrated best efficacy for reducing glucose levels, followed by glucagon-like peptide-1 receptor agonists (SMD=-0.39), dietary interventions (SMD=-0.37) and aripiprazole augmentation (SMD=-0.34), whereas insulin resistance improved the most with metformin (SMD=-0.75) and rosiglitazone (SMD=-0.44). Topiramate had the greatest efficacy for triglycerides (SMD=-0.68) and low-density lipoprotein (LDL)-cholesterol (SMD=-0.80), whereas metformin had the greatest beneficial effects on total cholesterol (SMD=-0.51) and high-density lipoprotein (HDL)-cholesterol (SMD=0.45). Lifestyle interventions yielded small effects for triglycerides, total cholesterol and LDL-cholesterol (SMD=-0.35 to -0.37). Only exercise interventions increased exercise capacity (SMD=1.81). Despite frequent physical comorbidities and premature mortality mainly due to these increased physical health risks, the current evidence for pharmacological and non-pharmacological interventions in people with schizophrenia to prevent and treat these conditions is still limited and more larger trials are urgently needed.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019. PMID: 30600626. doi:10.1002/wps.20614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。